Barron\'s - 16.09.2019

(backadmin) #1

September 16, 2019 BARRON’S M7


The Striking Price


Options


Bank of America Is Worth a Bet


By Steven M. Sears


SAM ZELL WAS RECENTLY ON CNBC, LISTENING


totheusualpalaverabouteverythingthat


couldgopossiblygowrongintheworldat


anymoment.Finally,theblunt-talking,self-


made billionaire made an important point


about market pundits.


“Wepredictedthatit’sgoingtobethis,


and we’re worried about this, and we’re


worried about that, and meanwhile the


gamekeepsgoing,”saidZell,whomadehis


fortune in real estate.


Real money is often made when others


think there isn’t any opportunity and the


risks seem high. The saga ofBank of


America(ticker: BAC), which was almost


destroyedduringtheglobalfinancialcrisis,


illustrates the lesson well.


Inthepastdecade,thebank’sstockprice


hasdoubledandtripledandthensome.This


columnlongchampionedthestockduringits


darkest hours, and has never stopped. We


recommended buying the stock and using


upside call options to supercharge the ad-


vance since Bank of America, which closed


Friday at $30.17, was in the single digits.


(Callsincreaseinvaluewhentheassociated


securityrises.)Sincethen,CEOBrianMoy-


nihan has turned the bank into a power-


house,andWarrenBuffetthasbecomeBank


of America’s largest shareholder.


Amidtalkofacomingrecessionandex-


pectations that the Federal Reserve is


about to lower interest rates again—theo-


reticallycrimpingfinancialstocks—it’sim-


portanttorememberthatbuyingstuffthat


iswildlyoutoffavorishistoricallyagreat


way to make money.


True, BofA, like other financial stocks,


has recently popped higher, but it seems


unable to definitively stay above $30. And


now J.P. Morgan is telling its clients that


BofA’s stock should shine.


Shawn Quigg, a derivatives strategist,


predictsthatthestockcouldrallyonacom-


bination of progress on the trade war, an


accommodative Fed, a steepening yield


curve,orevenhedgefundsadjustingport-


folios, which could trigger a style rotation


intobatteredstocks,sparkingachainreac-


tion of short covering, fundamental flows,


andequitylong-shortportfoliorebalancing


by quantitative investors.


InvestorscouldconsiderbuyingBankof


America’sOctober$30callsthatexpireon


Oct.25andcost$1.14.Thetradepositions


investorsattheforefrontofpotentiallyfa-


vorable events and lets them take advan-


tage of cheap implied volatility.


Bank of America’s one-month at-the-


money options are priced without a greed


premium,eventhoughtheremightbealot


tobegreedyabout.Ifthetradeworks,and


thebankpopsto,say,$34byexpiration,the


call is worth $4. If the stock is below the


strike at expiration, the trade fails.


During the past 52 weeks, Bank of


America stock has ranged from $22.66 to


$31.37andisup0.1%.Sharesareup22.4%


this year, two percentage points ahead of


the S&P 500 index.


To be sure,the single most important


thing about Bank of America is arguably


that it is a well-run company with a CEO


whoknowshisbusinessbecauseherebuilt


itafterhispredecessornearlydestroyedit.


The stock’s 2.4% dividend yield is like a


cherry atop a sundae.


Atextbookcouldbewrittenaboutallof


the risk factors facing the financial sector,


butifinterestratesareloweredandmoney


flows into stocks, as predicted, just about


anythingshouldadvance,especiallystocks


withcompetitiveyields—eveniftheassoci-


ated company’s business is challenged by


the drag of lower rates. If Moynihan em-


bracesthemomentanddoesmoretoboost


thedividendandbuybackstock—reward-


ing everyone who stuck with him through


thenastydays—BofAwillpopevenhigher.


Soundintriguing?ConsiderfollowingJ.P.


Morgan’s call trade, or just buy the stock


andsellsomeputsthatexpireinsixmonths


withstrikepricesjustbelowthestockprice.


These days, investing is too often dis-


cussedlikeasportingmatchortogetpeo-


pletoclickonwebsitelinks.Regardlessof


whathappensintheshortterm,peoplewill


alwaysneedtoborrowandmanagemoney,


and the game will keep going.


Equity Options


CBOE VOLATILITY INDEX


VIX Close VIX Futures

10


15


20


25


30


35


40


O NDJ FMAM J J A S

Daily Values Source: CBOE

THE EQUITY-ONLY PUT-CALL RATIO


Put-Call Ratio S&P 500 Index

55


90


125


160


195


230


265


O NDJ FMAM J J A S

Source: McMillan Analysis Corp.

SPX SKEW


Implied volatility %

7


8


9


10


11


12


13%


O NDJ FMAM J J A S

Source: Credit Suisse Equity Derivatives Strategy

NDX SKEW


Implied volatility %

8


9


10


11


12%


O NDJ FMAM J J A S

Source: Credit Suisse Equity Derivatives Strategy

Skew indicates whether the options market expects a stock-market advance or decline. It measures the difference
between the implied volatility of puts and calls that are 10% out of the money and expire in three months. Higher
readings are bearish.

Week'sMostActive


Company Symbol TotVol Calls Puts AvgTotVol IV%ile Ratio

National Vision EYE 23674 21018 2656 388 74 61.0


Invacare IVC 10389 7271 3118 244 88 42.6


Acadia Healthcare ACHC 16300 15995 305 988 55 16.5


Viavi Solutions VIAV 94101 91473 2628 6180 87 15.2


Park City PCYG 2532 1993 539 168 100 15.1


Rent-A-Center RCII 34948 33363 1585 2964 3 11.8


Avon Products AVP 22877 8814 14063 2208 4 10.4


Constellium CSTM 36707 36364 343 3592 9 10.2


The Lovesac LOVE 4588 2847 1741 488 76 9.4


Washington Prime WPG 13518 8629 4889 1524 96 8.9


Dave & Busters PLAY 40548 21288 19260 4608 26 8.8


Ally Financial ALLY 65567 59097 6470 8416 42 7.8


Immunogen IMGN 8886 8737 149 1148 40 7.7


Restoration Hardware RH 107196 61619 45577 16224 3 6.6


Ligand Pharm LGND 10238 1575 8663 1708 88 6.0


USA Technologies USAT 30769 24974 5795 5492 64 5.6


Acadia Pharm ACAD 27652 15598 12054 5120 48 5.4


Simon Property SPG 85960 8959 77001 16100 75 5.3


Agios Pharm AGIO 11554 1123 10431 2220 66 5.2


Moneygram MGI 17075 11414 5661 3388 81 5


Thistableofthemostactiveoptionsthisweek,ascomparedtoaverageweeklyactivity–notjustrawvolume.Theideaisthatthe
unusuallyheavytradingintheseoptionsmightbeapredictorofcorporateactivity–takeovers,earningssurprises,earningspre-
announcements,biotechFDAhearingsordrugtrialresultannouncements,andsoforth.Dividendarbitragehasbeeneliminated.In
short,thislistattemptstoidentifywhereheavyspeculationistakingplace. Theseoptionsarelikelytobeexpensiveincomparisonto
theirusualpricinglevels.Furthermore,manyofthesesituationsmayberumor-driven.Mostrumorsdonotprovetobetrue,soone
shouldbeawareoftheseincreasedrisksiftradinginthesenames
RatioistheTotVoldividedbyAvgTotVol.IV%ileishowexpensivetheoptionsareonascalefrom0to100.

Source:McMillanAnalysis

Free download pdf